• Mereo BioPharma received a Nasdaq notice extending its deadline to regain the $1 minimum bid-price requirement to Feb. 16, 2027.
• Compliance requires the ADS closing bid price to hold at $1 or more for at least 10 consecutive business days.
• Failure to regain compliance by the deadline triggers a Nasdaq delisting notice, with an option to appeal to a hearings panel.
• The notices do not immediately affect the ADS listing on the Nasdaq Capital Market.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mereo BioPharma Group plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-356168), on August 19, 2026, and is solely responsible for the information contained therein.